Rezolute, Inc. (RZLT)
| Market Cap | 493.08M -11.3% |
| Revenue (ttm) | n/a |
| Net Income | -81.49M |
| EPS | -0.80 |
| Shares Out | 104.47M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,220,243 |
| Open | 4.770 |
| Previous Close | 4.660 |
| Day's Range | 4.650 - 4.870 |
| 52-Week Range | 1.070 - 11.457 |
| Beta | 0.62 |
| Analysts | Buy |
| Price Target | 7.67 (+62.5%) |
| Earnings Date | Sep 16, 2026 |
About RZLT
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for RZLT stock is "Buy." The 12-month stock price target is $7.67, which is an increase of 62.50% from the latest price.
News
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia...
Rezolute Slides: Corporate presentation
Rezolute has posted slides in relation to its latest quarterly earnings report, which was published on June 26, 2026.
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from the Company's Phase 3 sunRIZE study in congenita...
Rezolute price target raised to $11, named a Best Idea at Guggenheim
Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Rezolute (RZLT) to $11 from $6 and keeps a Buy rating on the shares, which the analyst is also naming…
Rezolute Transcript: Jefferies Global Healthcare Conference 2026
Interim tumor HI data show strong efficacy, with top-line results and regulatory updates expected in the second half of the year. Both tumor and congenital HI programs are on track for potential BLA filings in 2025, with robust pricing and a 3,000-patient initial market opportunity.
Rezolute Slides: FY 2026
Rezolute has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 4, 2026.
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
REDWOOD CITY, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia...
Rezolute price target raised to $14 from $10 at Maxim
Maxim raised the firm’s price target on Rezolute (RZLT) to $14 from $10 and keeps a Buy rating on the shares. The firm cites the company having announced interim data…
Rezolute price target raised to $6 from $5 at Wedbush
Wedbush analyst Yun Zhong raised the firm’s price target on Rezolute (RZLT) to $6 from $5 and keeps an Outperform rating on the shares. The interim data that Rezolute reported…
Rezolute upgraded to Outperform from Market Perform at Citizens
Citizens upgraded Rezolute (RZLT) to Outperform from Market Perform with an $11 price target The interim Phase 3 results for ersodetug in tumor hyperinsulinism increase confidence that the approval pa...
Rezolute price target raised to $6 from $5 at BTIG
BTIG raised the firm’s price target on Rezolute (RZLT) to $6 from $5 and keeps a Buy rating on the shares after the company provided an interim update on its…
Rezolute price target raised to $14 from $10 at Maxim
Maxim raised the firm’s price target on Rezolute (RZLT) to $14 from $10 and keeps a Buy rating on the shares after the company provided an interim update on its…
Rezolute provides interim update on ersodetug study
Rezolute (RZLT) provided an interim update on its ongoing open-label Phase 3 study of ersodetug in tumor HI. With eight participants enrolled in upLIFT to date, comprising both insulinoma and…
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Study now 50% enrolled 6 of 8 participants have already met the responder criterion for the study's primary endpoint Topline results for the fully enrolled open-label study are expected in the second ...
Rezolute price target raised to $10 from $4 at Maxim
Maxim raised the firm’s price target on Rezolute (RZLT) to $10 from $4 and keeps a Buy rating on the shares after its Q3 results. The company’s Ersodetug, which had…
Rezolute reports Q3 EPS (16c), consensus (17c)
Cash, cash equivalents and investments in marketable securities were $120.3M as of March 31, compared with $167.9M as of June 30, 2025.
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all for...
Rezolute Earnings release: Q3 2026
Rezolute released its Q3 2026 earnings on May 12, 2026, summarizing the period's financial results.
Rezolute Quarterly report: Q3 2026
Rezolute has published its Q3 2026 quarterly earnings report on May 12, 2026.
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all for...
Rezolute Slides: Corporate presentation
Rezolute has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Rezolute presents results from Phase 3 sunRIZE study of ersodetug at PES 2026
Rezolute (RZLT) announced that expanded analyses from the Phase 3 sunRIZE study of ersodetug in patients with congenital HI were presented at the Pediatric Endocrine Society 2026 Annual Meeting. The…
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
Includes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrate significant and consistent improvements in glycemic control in ersodetug treatment arms compared t...
Rezolute, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 24, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Rezolute, Inc., (“Rezolute" or the "Company") (NASDAQ: RZLT) investors that the firm has initiated an investigation into po...
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates